TIBET PHARMA(SH:600211)2021-04-26 16:00Financial Performance - Operating revenue for the period was ¥494,293,289.21, representing a significant increase of 66.55% year-on-year[11]. - Net profit attributable to shareholders was ¥157,178,601.77, up 22.29% from the same period last year[11]. - The company reported a net profit excluding non-recurring gains and losses of ¥142,985,548.63, a year-on-year increase of 66.26%[11]. - Operating revenue for the first quarter was CNY 494.29 million, an increase of CNY 197.51 million or 66.55% compared to the same period last year, driven by significant sales growth of the biological product[24]. - The company reported a significant increase in sales revenue from CNY 391,731,090.91 in Q1 2020 to CNY 539,039,417.33 in Q1 2021, marking a growth of 37.7%[46]. - The company’s earnings per share (EPS) for Q1 2021 was ¥0.63, down from ¥0.73 in Q1 2020[43]. - The total comprehensive income for Q1 2021 was ¥169,334,500.48, an increase from ¥153,131,762.47 in Q1 2020[43]. Cash Flow - Net cash flow from operating activities amounted to ¥220,317,632.56, reflecting a 59.23% increase compared to the previous year[11]. - The net cash flow from investing activities decreased by CNY 3,525.20 million, primarily due to payments for project construction and milestone payments to partners[25]. - Cash flow from operating activities for Q1 2021 was CNY 220,317,632.56, an increase of 59.3% compared to CNY 138,364,960.42 in Q1 2020[47]. - Cash flow from investing activities showed a net outflow of CNY 324,030,839.64 in Q1 2021, compared to a net inflow of CNY 28,489,179.17 in Q1 2020[48]. - The total cash and cash equivalents at the end of Q1 2021 were CNY 705,076,989.66, down from CNY 652,910,810.34 in Q1 2020[49]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,228,301,233.43, an increase of 9.65% compared to the end of the previous year[11]. - Non-current assets totaled ¥1,757,303,851.40, compared to ¥1,593,173,288.20, reflecting an increase of about 10.3%[34]. - Current liabilities rose to ¥452,794,698.01 from ¥333,076,838.24, marking a significant increase of approximately 35.9%[34]. - Total liabilities amounted to ¥470,584,784.09, compared to ¥355,906,330.00, reflecting an increase of approximately 32.3%[36]. - The company’s total liabilities increased by ¥3,182,808.78 compared to the previous reporting period[55]. Shareholder Information - The total number of shareholders at the end of the reporting period was 67,300[15]. - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 32.28% of the shares[15]. - The major shareholder, Tibet Huaxi Pharmaceutical Group Co., Ltd., has pledged 30.842 million shares, accounting for 69.98% of its holdings and 12.44% of the company's total shares[29]. Investments and Projects - The company's construction in progress increased by CNY 1,377.84 million, a growth of 248.48%, primarily due to the initiation of a project by a subsidiary in Shanghai[22]. - The company completed the transfer of 89 out of 93 trademarks related to the acquired assets of AstraZeneca's Imdamo, with 27 out of 44 countries and regions having completed the MA conversion[26]. - The company has received approval for clinical trials of its mRNA COVID-19 vaccine in collaboration with Swei (Shanghai) Biotechnology Co., Ltd.[26]. - The company plans to continue to entrust AstraZeneca or Kangzhe (Hunan) Pharmaceutical Co., Ltd. for the production of Imdamo products after the marketing authorization holder change[26]. Financial Ratios and Returns - The weighted average return on equity increased by 0.80 percentage points to 5.91%[11]. - Basic earnings per share decreased by 13.70% to ¥0.63 due to a 40% increase in share capital compared to the previous reporting period[11]. Other Financial Metrics - The company’s tax and additional fees increased by CNY 17.20 million, a growth of 49.88%, due to the increase in sales revenue[24]. - The company reported a total cost of operations of ¥332,643,897.66 for Q1 2021, which is an increase from ¥198,141,264.78 in Q1 2020[41]. - Research and development expenses for Q1 2021 were ¥1,418,199.60, slightly up from ¥1,238,979.22 in Q1 2020[41].